BMY Q1 2022 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$124B

Q1 2022 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$11.6B+5.2% YoY

Gross Profit

$6.8B58.0% margin

Operating Income

$2.7B23.3% margin

Net Income

$1.3B11.0% margin

EPS (Diluted)

$0.59

QoQ Revenue Growth

-2.8%

Cash Flow

Operating Cash Flow

$3.8B

Free Cash Flow

$3.6B

Stock-Based Comp.

$107M

Balance Sheet

Total Assets

$103.0B

Total Liabilities

$71.4B

Stockholders' Equity

$31.6B

Cash & Equivalents

$12.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11.6B	$11.1B	+5.2%
Gross Profit	$6.8B	$6.1B	+11.0%
Operating Income	$2.7B	$2.2B	+23.4%
Net Income	$1.3B	$2.0B	-36.8%

Revenue Segments

Eliquis

$3.2B28%

Revlimid

$2.8B24%

Opdivo

$1.9B17%

Pomalyst/Imnovid

$826M7%

Orencia

$792M7%

Yervoy

$515M4%

Sprycel

$483M4%

Mature Products And All Other

$462M4%

Abraxane

$214M2%

Reblozyl

$156M1%

Abecma

$67M1%

Breyanzi

$44M0%

Zeposia

$36M0%

Opdualag

$6M0%

Geographic Segments

UNITED STATES

$7.7B66%

Europe

$2.4B21%

Rest Of World

$1.3B11%

Other Region

$227M2%